Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy

Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy

US Patent 11466324 · Granted Oct 11, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Complexes between CD40 and compounds comprising benzimidazole moieties2025
Antibody molecules which bind CD222025
Treatment of hidradenitis suppurativa using JAK inhibitors2025
JAK1 pathway inhibitors for the treatment of prurigo nodularis2025
JAK1 pathway inhibitors for the treatment of gastrointestinal disease2024
JAK inhibitor with a vitamin D analog for treatment of skin diseases2024
Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Li2024
JAK1 pathway inhibitors for the treatment of vitiligo2024
Combination therapy comprising JAK pathway inhibitor and rock inhibitor2024
Antibody molecules which bind CD452023
Method of identifying potential inhibitors of APO TNFα trimers2023
JAK1 pathway inhibitors for the treatment of gastrointestinal disease2023